Adtec visits Taiwan for SteriPlas expansion project


Who better to facilitate the expansion of the SteriPlas Premium Cold Plasma in the SE Asia market but the leading medical distributor, SG Biomedical. Adtec Healthcare Limited joins SG Biomedical in Taiwan to complete the introduction of three SteriPlas medical devices in the leading wound care hospitals.

Over 30 patients have so far been treated ranging from Diabetic Foot Ulcers, LVAD infections, Burn wounds, Vascular and Orthopaedic wounds and so on. All patients have had chronic infection with biofilm prior to being introduced to the SteriPlas. Some wounds have been non-healing for 4 years!


We are happy to report that over continued twice weekly use over the last two months, all patients are responding very well with most having been fully healed and no relapse of infection.


If you are within the Taiwan region and you are interested to learn more, please contact us so that we may introduce you to our partner.

Adtec's World Map

Launching an innovative and unknown technology on the medical market has only been successful due to the many years of clinical evidence and trust that we have accrued. From being the first company worldwide to introduce Cold Plasma on wounds in clinical trials to now being the leading manufacturer behind the most effective Cold Plasma medical device, Adtec Healthcare Limited has the strongest experience on how to successfully combat infections stalled by biofilm.


Our global presence of the SteriPlas Premium Cold Plasma is increasing with multiple clinics and distributors endorsing our medical device for chronic infection management of wounds, surgical site infections and medical dermatology.


There are multiple clinics in each country that help to spread the word of the benefit that our medical device brings to non-healing infections. Unfortunately, there is not enough space on this small map to reflect this!


We have also significantly increased our Distributor portfolio into new countries who are rapidly bringing the SteriPlas to their clinics and customers, with plans to expand even further into new territories which we are currently working on.

To learn more about the successes of our dense and rich Cold Plasma, send us a message at We are also keen to reach out to new distributors who also wish to bring our Cold Plasma to their territories.

Effective at deep and difficult to treat infection areas


The Premium Cold Plasma from our SteriPlas can kill all bacterial species, regardless of the resistance profile or if they are protected within biofilm. Due to the dense and rich Cold Plasma created, this includes treating difficult to reach areas such as LVAD drivelines, catheters and stoma infections.

Propelled by the gas flow, the Cold Plasma will travel down the gaps around the crevices of the infected driveline until it reaches the site of biofilm which is typically deep underneath the skin fold.

The enhanced physical mode of action of the SteriPlas is delivered quickly and effectively, eradicating bacteria which would otherwise have been resistant to conventional therapies such as antibiotics. These benefits are widely documented including the safety of having no side effects associated to our reliable and consistent Cold Plasma.


The adoption of the SteriPlas has been significantly increasing across the globe for LVAD infection treatments with promising results. To learn more about the SteriPlas, send us an email at

Arab Health Exhibition 2024

We’re excited to be attending the Arab Health Exhibition next week to meet with our new partners across the Middle East. This year Adtec Healthcare Limited welcomes the expansion of our Cold Plasma to the MENA region, facilitated by our Distributors in their leading fields of wound care and surgical site infections.

If you would like to secure your meeting with us during the Arab Health show, please send us an email at

The Power of Going Large

The SteriPlas boasts a wide clinical bibliography of clinical trials and publications, documenting the strong clinical efficacy coupled with no side effects reported. This benefits to patients suffering from non-healing wounds infected with biofilm whereby quick 2 minute treatment sessions are able to destroy all bacteria present and heal patients in as quick as 1 week.

To make such a statement as the above requires strong, reputable, and quality-driven results which we are thankful to have. But to collect these results and optimise the technical build of the SteriPlas has taken many years. From our first ever clinical trial on wounds approximately two decades ago to today, the SteriPlas has had its fair share of changes.

Whilst there have been multiple beneficial changes, the overall size of the SteriPlas has remained the same for a crucial reason. The Steriplas is the size it is to produce the optimum plasma for clinical efficacy using microwave argon plasma. Whilst Cold Plasma can still be generated with various technologies, it cannot be done in the same dense and rich manner delivering antibiofilm results. Crucial components to ensure the consistency and reliability may be lost. Most cold plasmas will have antibacterial efficacy against planktonic strains in in-vitro non-competing environments, but chronic wounds are a complex topography of biofilm, exudate, slough, living and necrotic tissue.

Adtec Plasma Technology has developed many Cold Plasma devices since its existence from small pens, portable shoulder strap machines to large medical devices. Our legacy device, the SteriPlas, remains the clinical leader in Cold Plasma medicine for wounds, surgical site infections and medical dermatology conditions.

Does more power lead to enhanced wound care treatment?

In simple terms, the answer is yes. To look more in depth at the question we need to understand how the Cold Plasma is generated and the mechanics behind it. The SteriPlas boasts a large 12cm2 treatment area which fully covers typical chronic wounds expected in wound clinics. There are of course much larger wounds than 12cm2 but thanks to the mechanics behind the SteriPlas it only requires a 2 minute treatment time for each 12cm2 area it covers.

There are some Cold Plasma devices that claim a 100cm2 treatment area but how does the power behind it compare to the SteriPlas? It is without question, the SteriPlas is one of the largest Cold Plasma medical devices on the medical market and it is strategically large for a reason. It is the only Cold Plasma medical device able to produce a deep, dense, and rich Cold Plasma. To produce repeatable and consistent results with antibiofilm properties, there are a series of crucial internal components in the SteriPlas that collectively work to perform this including the 200W 2.45GHz microwave generator, plasma ignition control, mass flow controller, arm to hold plasma treatment head in place during use, control system linked to interlock and alarms, cooling system and safety circuits.

Smaller Cold Plasma devices with larger treatment areas generate different plasmas. Whilst some reduction of bacterial load may be observed with their use, it is strictly limited to superficial and small wounds certainly with no biofilm presence. To combat biofilm within wounds, the Cold Plasma does need to be deeply penetrating and to do this more power and plasma density is certainly required.

The SteriPlas, by default, is designed to target deep, chronic and severe infections with biofilm complications within the wound. Peer reviewed clinical evidence for smaller devices with larger treatment areas are still limited.

The SteriPlas boasts a wide clinical bibliography of 80+ peer reviewed clinical trials and studies. It is the leader in the Cold Plasma medical market for a reason.

To learn more about our medical device, send us an email

Seasons Greetings!

Seasons Greetings!
May the new year be even more productive and cheerful than the previous one. Thank you to all our customers, distributors, suppliers and to everyone who has supported us. We would not be where we are today if not for you. Wishing you all the best this season and always.

Is all Cold Plasma created equal?

There is no doubt a wide variety of Cold Plasma medical devices currently on the market and new Cold Plasma designs often being released by startup companies. But how do these devices compare in efficacy, strength, reliability, and performance?

To say all Cold Plasmas are the same, which some companies (shockingly) do, would be farfetched and misleading. This is like comparing a race between a sports car and a bicycle or saying all liquids or gases are the same – the product and plasma components are technically very different.

When Adtec first developed Cold Plasma and carried out the first ever clinical trials on wounds many years ago, our data showed the remarkably strong and reputable results that we still deliver today. This is exclusively for our range of Adtec Cold Plasma medical devices. Our data is often cited by other Cold Plasma companies as their own medical devices lack strength in efficacy and performance in clinical data.

The important questions to raise are:
- What is the frequency of Cold Plasma applications per week to achieve full healing?
- How deep can the Cold Plasma penetrate?
- How quick can the Cold Plasma be applied?
- What is the delivery method of Cold Plasma?
- Is Cold Plasma limited to acute and superficial wounds or can it treat deep, chronic wounds with biofilm?
- What is the clinical evidence for the product itself and not cold plasma in general?

Whilst there are some Cold Plasma medical devices that do not satisfy the requirements met by a wound clinician, the SteriPlas does remain the leader and favorable choice in the Cold Plasma medical market. A once per week treatment time of 2 minutes per 12cm2 has been shown to accelerate healing in chronic, problematic, and non-healing wounds with biofilm presence. This cannot be said for all other Cold Plasma devices which recommend treatment once per day and are only indicated for acute, small, and superficial wounds certainly with no biofilm presence.

Due to its overall larger size which houses crucial components ensuring a consistent, reliable and therapeutic Cold Plasma, the SteriPlas is the only microwave-energy, Cold Argon Plasma medical device which delivers deep, dense and rich Cold Plasma able to kill all bacterial species embedded within biofilm. We can boast that no side effects have been reported with our Cold Plasma medical device since the history of its making.

For more information about the SteriPlas and how we have changed the way that wounds are healed, please visit our page:

Why Bigger is Better?

The SteriPlas has been widely documented in clinical trials and publications for its strong antibacterial efficacy and accelerated healing properties. Being the first medical device worldwide to show just how effective Cold Plasma can be from clinical trials on wounds, it is still the only medical device covering a larger 12cm2 treatment area using microwave-energy, safe, reputable, and consistent Cold Plasma. It is also the only medical device that can treat wounds within this size for only 2 minutes to achieve antibiofilm efficacy with no reported side effects.

So how does it compare to a Cold Plasma Pen?

As useful as Plasma pens can be for very small and superficial wounds without biofilm, 2 minutes is required for the treatment area equivalent to a few mms.
This means to treat a large and deep wound that the SteriPlas can do in 2 minutes (hands-free), then Plasma Pens would require in excess of 30 minutes with handheld use to reduce the bacterial load present in the same wound area . The SteriPlas is the only medical device with antibiofilm efficacy due to its dense and deep penetration capabilities making it the leader in Cold Plasma medicine.

Adtec to present at the Advanced Wound Care Summit EU

We’ve been invited to speak at the Advanced Wound Care Summit EU conference in London this week. Our Senior Business Development Manager, Jeiram, will be part of the Executive Speakers Line Up at the opening session “Panel Prioritising Clinical Data & Health Economic Evidence” at 8.55am on Tuesday 28th November.
Adtec Healthcare strives for strong and reputable clinical evidence. Over the years of our existence, we have collected a total of 80+ peer reviewed clinical studies on the SteriPlas Premium Cold Plasma which has resulted in quality Health Economics data for our medical device.

We understand the absolute importance of Health Economics data to back the claims of medical devices. With our clinical evidence, we can present the promising results of the SteriPlas for significantly accelerating wounds stalled with biofilm and reducing bed occupancy, antibiotics usage and the financial burden posed on hospitals.